In a study presented in this issue of the *Journal*, Lachowicz-Scroggins and coworkers (pp. [1076--1085](10.1164/rccm.201810-1869OC)) elegantly investigated the role of extracellular DNA (eDNA), neutrophil extracellular traps (NETs), and inflammasome activation in nonsmoking patients with severe asthma ([@bib1]). The authors examined induced sputum from 399 obese patients with asthma (66% females, mean \[±SD\] age, 48 ± 1 yr; body mass index \[BMI\], 33 ± 9; 89% under regular treatment with inhaled corticosteroids, 62% under regular treatment with a high dose \[not otherwise specified\] of inhaled corticosteroids, and 16% under regular treatment with systemic glucocorticoids; comorbidities \[including bronchiectasis\] and their treatment not reported) from the Severe Asthma Research Program-3 cohort and two control groups of 59 (61% females; mean age, 38 ± 1 yr) and 35 (51% females; mean age, 40 ± 1 yr) healthy overweight subjects with a mean (±SD) BMI of 25 ± 6 and 27 ± 5, respectively. None of the subjects were current smokers or had a significant history of smoking. The main results of this study were that 13% of the patients with severe asthma had a high eDNA sputum level (\>3.8 μg/ml), and this subset of patients had the worst asthma control (and also a frequent history of mucus hypersecretion and frequent use of oral glucocorticoids for maintenance of asthma control). The presence of increased sputum eDNA was also associated with sputum neutrophilic inflammation, increased NET formation, and inflammasome activation. *In vitro* NETs cause human bronchial epithelial cell cytotoxicity that is preventable by DNase treatment.

NLRs (nucleotide oligomerization domain--like receptors) are a particular type of intracellular pattern recognition receptor that recognize pathogen-associated molecular patterns and the host-derived signals called danger-associated molecular patterns ([@bib2]) ([Figure 1](#fig1){ref-type="fig"}). A typical inflammasome is composed of an NLR, an adaptor protein such as ASC, and an effector caspase that activates proinflammatory cytokines. Within the NLRP3 complex, autocatalytic cleavage of procaspase 1 to active caspase-1 enables the removal of IL-1β and IL-18 prosequences, resulting in biologically active forms and thereby initiating T-helper cell type 1 (Th1) and Th17 adaptive immune responses ([@bib2], [@bib3]) ([Figure 1](#fig1){ref-type="fig"}). Gasdermin D (membrane pore-forming) activation by cleavage from both caspase-1 and caspase-4/5/11 causes a form of programmed cell death termed pyroptosis ([@bib4]). NRLP3 inflammasome activation also causes the release of alarmins (molecules released from a damaged or diseased cell that can stimulate a sterile immune or inflammatory response) such as IL-33 (another member of the IL-1 family, which acts through the receptor ST2) and atypical chemokines such as HMGB-1 ([@bib5]). The NLRP3 inflammasome is activated by many stimuli, including NETs and double-stranded DNA ([@bib2]) ([Figure 1](#fig1){ref-type="fig"}).
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NETs are composed of decondensed chromatin fibers (containing double-stranded DNA) coated with antimicrobial granular and cytoplasmic proteins such as myeloperoxidase, neutrophil elastase, and α-defensins ([@bib6]). Neutrophil extrusion of NETs may induce tissue damage and inflammasome activation, and neutrophils use an inflammasome- and gasdermin D--dependent mechanism to activate NETosis as a defense response against cytosolic bacteria ([@bib7]).

This topic has been partially addressed in previous studies. In a female mouse model, NLRP3 inflammasome responses were found to drive experimental severe, steroid-resistant asthma ([@bib8]). The U-BIOPRED (Unbiased Biomarkers in Prediction of Respiratory Disease Outcomes) Consortia Project Team demonstrated inflammasome activation in induced sputum from patients (smoking and nonsmoking) with severe asthma compared with nonsmoking patients with mild/moderate asthma and healthy control subjects that was associated with sputum neutrophilia and increased IL-1β protein levels ([@bib9]). In that study, most (64%) of the nonsmoking patients with severe asthma were overweight females (mean BMI 29) ([@bib9]), and neutrophilic severe asthma was defined using a cutoff of induced sputum neutrophils of mean ≥ 74% ([@bib9]), compared with a median of 51% (interquartile range 34--74) induced sputum neutrophils in the study by Lachowicz-Scroggins and coworkers ([@bib1]).

There are some potential biases in the study by Lachowicz-Scroggins and coworkers. First, all of the patients with severe asthma included in their study were obese and compared only with healthy overweight control subjects, and not also with cohorts of nonobese subjects with asthma of different severities and healthy obese control subjects. In fact, obesity alone may influence NET formation ([@bib10]) and NLRP3 inflammasome activation ([@bib11]), and weight loss decreases peripheral blood neutrophil NET formation and inflammasome activation ([@bib12], [@bib13]). In one recent study, sputum NLRP3 mRNA and IL-1β protein levels were found to be significantly increased in obese versus nonobese patients with stable asthma ([@bib13]). Furthermore, the authors provided no information about the diet of their subjects, and it has been demonstrated that in obese patients with stable asthma an acute challenge with a meal high in saturated fatty acids increases their sputum neutrophilia ([@bib13]).

Another potential bias may arise from the glucocorticoid (inhaled and systemic) treatment used in the study. NET formation was shown to be downregulated by glucocorticoids in an animal model of asthma ([@bib14]), whereas intriguing data from other animal models suggest that glucocorticoids may be mandatory for inflammasome activation ([@bib15]). It is worth noting that only 13% of the patients with severe asthma had a high eDNA sputum level, and this percentage is somewhat similar to that observed in the same patients under regular treatment with systemic glucocorticoids.

Future studies should also use better techniques, such as sputosorption ([@bib16]), and measure the whole spectrum of inflammasome activation, including IL-1Ra ([@bib17]), IL-33, gasdermin D, and HMGB-1. These new and exciting data have potential therapeutic implications for this subset of obese nonsmoking patients with severe asthma. For example, the effect of fasting on asthma inflammasome activation was investigated in a recently completed pilot observational clinical study (<https://clinicaltrials.gov/NCT02471300>). Currently approved inhibitors of IL‐1β that may be tested in controlled clinical trials include anakinra (recombinant human IL‐1R antagonist \[[@bib18]\]), rilonacept (recombinant soluble IL‐1R), and canakinumab (humanized anti--IL‐1β monoclonal antibody \[[@bib19]\]). Two selective NLRP3 inflammasome inhibitors are β‐hydroxybutyrate (a ketone body produced during periods of starvation \[[@bib20]\]) and the oral small molecule MCC950 ([@bib8]). A potential advantage of these selective NLRP3 inflammasome inhibitors over IL‐1β blockers is that NLRP3‐specific agents may also target IL‐18 but permit IL‐1β activation by other inflammasomes. This may be important for the response to infection and other cellular processes, and also target the noncanonical effects of the inflammasome, which may be advantageous for controlling inflammasome‐mediated diseases ([@bib21]).
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